The South Korea Hematology Analyzers and Reagents Market was valued at $64 Million in 2026 and projected to reach to $76.5 Million by 2031, representing a compound annual growth rate of CAGR 3.6%. South Korea's hematology analyzers and reagents market is positioned for steady expansion driven by the country's sophisticated healthcare system and emphasis on preventive diagnostics.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea's hematology analyzers and reagents market is valued at USD 64.0 million in 2026, with projections to reach USD 76.5 million by 2031, representing steady growth in the mature healthcare sector.
The market expands at a CAGR of 3.6% through 2031, reflecting slower growth compared to the global CAGR of 6.4%, indicating a stabilized and well-established market with consistent demand.
South Korea's advanced healthcare infrastructure and high diagnostic testing adoption rates drive sustained demand for automated hematology solutions across hospitals, diagnostic centers, and clinical laboratories.
The South Korean market represents a mature healthcare ecosystem with established diagnostic protocols, strong regulatory frameworks, and high penetration of automated hematology systems in medical facilities.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | POINT-OF-CARE ANALYZERS (Usage Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 6.4% from 2026 to 2031 |
| Largest Segment | STANDALONE ANALYZERS (Usage Type) |
| Market Size Base Year (Billions) | ~USD 7.58 (2026) |
| Revenue Forecast (Billions) | ~USD 10.33 (2031) |
| Segments Covered | Price Range, Usage Type, Product & Service, Type, Application, End User |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | ||
| HAEMONETICS | United States | ||
| EIKEN CHEMICAL CO., LTD. | Japan | ||
| SYSMEX CORPORATION | Japan | ||
| ABBOTT | United States | ||
| DANAHER CORPORATION | United States | ||
| SIEMENS HEALTHINEERS AG | Germany | ||
| SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. | China | ||
| BIO-RAD LABORATORIES, INC. | United States | ||
| EKF DIAGNOSTICS HOLDINGS PLC | United Kingdom | Public Company | PoC hematology instruments (DiaSpect Tm, Hemo Control, Hemo Vet, HemataStat II),Hematology reagents and consumables,Slide stainers and related accessories, |
BIOMERIEUX S.A. is a French in vitro diagnostics company specializing in microbiology, immunoassays, and molecular biology testing solutions for clinical and industrial applications.
HAEMONETICS is a United States-based medical technology company specializing in blood management and plasma collection systems for healthcare providers.
EIKEN CHEMICAL CO., LTD. is a Japanese chemical and diagnostics company manufacturing in vitro diagnostic reagents and laboratory testing products.
SYSMEX CORPORATION is a Japanese diagnostics company specializing in hematology, hemostasis, immunochemistry, and clinical chemistry analyzers and reagents.
ABBOTT is a United States-based diversified healthcare company with significant operations in diagnostics, including molecular, immunoassay, and point-of-care testing.
DANAHER CORPORATION is a United States-based conglomerate with a substantial diagnostics segment providing laboratory instruments, reagents, and software solutions.
SIEMENS HEALTHINEERS AG is a German healthcare company offering diagnostic imaging, laboratory diagnostics, and point-of-care testing solutions.
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. is a Chinese medical device and diagnostics company manufacturing patient monitoring, ultrasound, and laboratory diagnostic equipment.
BIO-RAD LABORATORIES, INC. is a United States-based life sciences and diagnostics company providing products for clinical diagnostics, quality control, and research applications.
EKF DIAGNOSTICS HOLDINGS PLC is a United Kingdom-based diagnostics company founded in 1990 with 301 employees, providing point-of-care and laboratory testing solutions.
South Korea's hematology analyzers and reagents market is estimated at USD 64.0 million in 2026.
South Korea's market is forecast to reach USD 76.5 million by 2031, representing a 3.6% CAGR from 2026 to 2031.
South Korea's market growth is driven by an aging population, rising hematological disease prevalence, laboratory automation adoption, and investment in precision medicine infrastructure.
South Korea's 3.6% CAGR reflects a mature, stable market with established healthcare systems, compared to higher-growth emerging markets in the Asia Pacific region.
South Korea's market is influenced by AI-enabled diagnostics, next-generation analyzer integration, point-of-care testing expansion, and continuous equipment modernization cycles.
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the hematology analyzers and reagents market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the hematology analyzers and reagents market. The primary sources from the demand side include OEMs, private and contract testing organizations, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
![]()
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.
To know about the assumptions considered for the study, download the pdf brochure
In this report, the market size of hematology analyzers & reagents was determined using the revenue share analysis of leading players. For this purpose, key market players were identified, and their market revenues were determined using insights gathered during the primary and secondary research phases. Secondary research included analyzing the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and senior marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

After arriving at the overall market size from the market size estimation process explained above, the global hematology analyzers and reagents market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the hematology analyzers and reagents market was validated using both top-down and bottom-up approaches.
The hematology analyzers and reagents market can be defined as the global industry involved in the design, development, and sale of instruments and consumables used for blood analysis. It involves the use of various types of hematology analyzers, including manual, semiautomatic, and automatic ones – 3-part differential analyzers, 5-part/6-part full-automatic analyzers, as well as POCT hematology testing systems. Tests performed with them include CBC, WBC differentials, hemoglobin analysis, and platelet counts. They are widely used in the diagnosis of anemia, infectious diseases, hematologic malignancies, and other blood disorders.
Reagents for hematology include diluents, lysing reagents, stains, controls/calibrators, and other consumables required in the course of testing to achieve accurate, reliable results. In addition to the hematology segment, the market includes hemostasis and immunohematology segments. Thus, it offers a wider range of products/services.
The market is expected to grow significantly due to rising demand for blood analysis across hospitals, labs, research institutes, and POCT sites. It is due to advancements in technology and automation in the industry.
Based on the provided market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the present global hematology analyzers and reagents market report:
Product Analysis
Company Information
Geographic Analysis
Full forecast, segment splits, and company analysis for all Hematology Analyzers and Reagents Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report